Investment analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences stock opened at $0.00 on Tuesday. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $1.48. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The stock has a market capitalization of $70,480.80, a P/E ratio of 0.00 and a beta of 1.52. The stock has a 50-day simple moving average of $0.01 and a 200 day simple moving average of $0.02.
Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient’s CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient’s tumor.
Featured Articles
Receive News & Ratings for Genocea Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genocea Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.
